rs190132116
Variant summary
Our verdict is Benign. The variant received -19 ACMG points: 0P and 19B. BP4_ModerateBP6_Very_StrongBP7BS1BS2
The NM_002047.4(GARS1):c.2190G>A(p.Glu730Glu) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000772 in 1,595,330 control chromosomes in the GnomAD database, including 8 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Consequence
NM_002047.4 synonymous
Scores
Clinical Significance
Conservation
Publications
- Charcot-Marie-Tooth disease type 2DInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: ClinGen, Labcorp Genetics (formerly Invitae), Orphanet
- neuronopathy, distal hereditary motor, type 5AInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Labcorp Genetics (formerly Invitae), Illumina, Laboratory for Molecular Medicine
- spinal muscular atrophy, infantile, James typeInheritance: AD Classification: MODERATE Submitted by: Ambry Genetics
Genome browser will be placed here
ACMG classification
Our verdict: Benign. The variant received -19 ACMG points.
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| GARS1 | ENST00000389266.8 | c.2190G>A | p.Glu730Glu | synonymous_variant | Exon 17 of 17 | 1 | NM_002047.4 | ENSP00000373918.3 | ||
| GARS1 | ENST00000675651.1 | c.2208G>A | p.Glu736Glu | synonymous_variant | Exon 17 of 17 | ENSP00000502513.1 | ||||
| GARS1 | ENST00000675810.1 | c.2088G>A | p.Glu696Glu | synonymous_variant | Exon 16 of 16 | ENSP00000502743.1 | ||||
| GARS1 | ENST00000675693.1 | c.2022G>A | p.Glu674Glu | synonymous_variant | Exon 18 of 18 | ENSP00000502174.1 | ||||
| GARS1 | ENST00000675051.1 | c.1989G>A | p.Glu663Glu | synonymous_variant | Exon 17 of 17 | ENSP00000502296.1 | ||||
| GARS1 | ENST00000674815.1 | c.1821G>A | p.Glu607Glu | synonymous_variant | Exon 17 of 17 | ENSP00000502799.1 | ||||
| GARS1 | ENST00000674851.1 | c.1821G>A | p.Glu607Glu | synonymous_variant | Exon 18 of 18 | ENSP00000502451.1 | ||||
| GARS1 | ENST00000444666.6 | n.*611G>A | non_coding_transcript_exon_variant | Exon 18 of 18 | 3 | ENSP00000415447.2 | ||||
| GARS1 | ENST00000674616.1 | n.*1904G>A | non_coding_transcript_exon_variant | Exon 18 of 18 | ENSP00000502408.1 | |||||
| GARS1 | ENST00000674643.1 | n.*1995G>A | non_coding_transcript_exon_variant | Exon 17 of 17 | ENSP00000501636.1 | |||||
| GARS1 | ENST00000674737.1 | n.*1528G>A | non_coding_transcript_exon_variant | Exon 18 of 18 | ENSP00000502464.1 | |||||
| GARS1 | ENST00000674807.1 | n.*463G>A | non_coding_transcript_exon_variant | Exon 16 of 16 | ENSP00000502814.1 | |||||
| GARS1 | ENST00000675529.1 | n.*2060G>A | non_coding_transcript_exon_variant | Exon 18 of 18 | ENSP00000501655.1 | |||||
| GARS1 | ENST00000675859.1 | n.*369G>A | non_coding_transcript_exon_variant | Exon 15 of 15 | ENSP00000502033.1 | |||||
| GARS1 | ENST00000676088.1 | n.*2132G>A | non_coding_transcript_exon_variant | Exon 19 of 19 | ENSP00000501884.1 | |||||
| GARS1 | ENST00000676140.1 | n.*1135G>A | non_coding_transcript_exon_variant | Exon 17 of 17 | ENSP00000502571.1 | |||||
| GARS1 | ENST00000676164.1 | n.*1641G>A | non_coding_transcript_exon_variant | Exon 17 of 17 | ENSP00000501986.1 | |||||
| GARS1 | ENST00000676210.1 | n.*1479G>A | non_coding_transcript_exon_variant | Exon 18 of 18 | ENSP00000502373.1 | |||||
| GARS1 | ENST00000676259.1 | n.*1622G>A | non_coding_transcript_exon_variant | Exon 17 of 17 | ENSP00000501980.1 | |||||
| GARS1 | ENST00000676403.1 | n.*275G>A | non_coding_transcript_exon_variant | Exon 16 of 16 | ENSP00000502681.1 | |||||
| GARS1 | ENST00000444666.6 | n.*611G>A | 3_prime_UTR_variant | Exon 18 of 18 | 3 | ENSP00000415447.2 | ||||
| GARS1 | ENST00000674616.1 | n.*1904G>A | 3_prime_UTR_variant | Exon 18 of 18 | ENSP00000502408.1 | |||||
| GARS1 | ENST00000674643.1 | n.*1995G>A | 3_prime_UTR_variant | Exon 17 of 17 | ENSP00000501636.1 | |||||
| GARS1 | ENST00000674737.1 | n.*1528G>A | 3_prime_UTR_variant | Exon 18 of 18 | ENSP00000502464.1 | |||||
| GARS1 | ENST00000674807.1 | n.*463G>A | 3_prime_UTR_variant | Exon 16 of 16 | ENSP00000502814.1 | |||||
| GARS1 | ENST00000675529.1 | n.*2060G>A | 3_prime_UTR_variant | Exon 18 of 18 | ENSP00000501655.1 | |||||
| GARS1 | ENST00000675859.1 | n.*369G>A | 3_prime_UTR_variant | Exon 15 of 15 | ENSP00000502033.1 | |||||
| GARS1 | ENST00000676088.1 | n.*2132G>A | 3_prime_UTR_variant | Exon 19 of 19 | ENSP00000501884.1 | |||||
| GARS1 | ENST00000676140.1 | n.*1135G>A | 3_prime_UTR_variant | Exon 17 of 17 | ENSP00000502571.1 | |||||
| GARS1 | ENST00000676164.1 | n.*1641G>A | 3_prime_UTR_variant | Exon 17 of 17 | ENSP00000501986.1 | |||||
| GARS1 | ENST00000676210.1 | n.*1479G>A | 3_prime_UTR_variant | Exon 18 of 18 | ENSP00000502373.1 | |||||
| GARS1 | ENST00000676259.1 | n.*1622G>A | 3_prime_UTR_variant | Exon 17 of 17 | ENSP00000501980.1 | |||||
| GARS1 | ENST00000676403.1 | n.*275G>A | 3_prime_UTR_variant | Exon 16 of 16 | ENSP00000502681.1 |
Frequencies
GnomAD3 genomes AF: 0.00410 AC: 619AN: 150958Hom.: 4 Cov.: 31 show subpopulations
GnomAD2 exomes AF: 0.00102 AC: 255AN: 249482 AF XY: 0.000879 show subpopulations
GnomAD4 exome AF: 0.000424 AC: 613AN: 1444244Hom.: 3 Cov.: 41 AF XY: 0.000384 AC XY: 276AN XY: 718396 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00410 AC: 619AN: 151086Hom.: 5 Cov.: 31 AF XY: 0.00406 AC XY: 300AN XY: 73802 show subpopulations
Age Distribution
ClinVar
Submissions by phenotype
not specified Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
not provided Benign:2
- -
- -
Charcot-Marie-Tooth disease type 2 Benign:1
- -
GARS1-related disorder Benign:1
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at